| Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2 JB Case, PW Rothlauf, RE Chen, Z Liu, H Zhao, AS Kim, LM Bloyet, ... Cell host & microbe 28 (3), 475-485. e5, 2020 | 393 | 2020 |
| Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2 K Suryamohan, D Diwanji, EW Stawiski, R Gupta, S Miersch, J Liu, ... Communications biology 4 (1), 475, 2021 | 149 | 2021 |
| Tailored tetravalent antibodies potently and specifically activate Wnt/Frizzled pathways in cells, organoids and mice Y Tao, M Mis, L Blazer, M Ustav, Z Steinhart, R Chidiac, E Kubarakos, ... Elife 8, e46134, 2019 | 85 | 2019 |
| The cell cycle timing of human papillomavirus DNA replication T Reinson, L Henno, M Toots, M Ustav Jr, M Ustav PLoS One 10 (7), e0131675, 2015 | 67 | 2015 |
| Development of a cellular assay system to study the genome replication of high-and low-risk mucosal and cutaneous human papillomaviruses J Geimanen, H Isok-Paas, R Pipitch, K Salk, T Laos, M Orav, T Reinson, ... Journal of virology 85 (7), 3315-3329, 2011 | 65 | 2011 |
| Identification and tracking of antiviral drug combinations A Ianevski, R Yao, S Biza, E Zusinaite, A Männik, G Kivi, A Planken, ... Viruses 12 (10), 1178, 2020 | 64 | 2020 |
| The transcription map of human papillomavirus type 18 during genome replication in U2OS cells M Toots, A Männik, G Kivi, M Ustav Jr, E Ustav, M Ustav PloS one 9 (12), e116151, 2014 | 39 | 2014 |
| Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay M Toots, M Ustav Jr, A Männik, K Mumm, K Tämm, T Tamm, E Ustav, ... PLoS pathogens 13 (2), e1006168, 2017 | 30 | 2017 |
| HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species G Kivi, K Teesalu, J Parik, E Kontkar, M Ustav, L Noodla, M Ustav, ... BMC biotechnology 16, 1-14, 2016 | 28 | 2016 |
| Bovine colostrum-derived antibodies against SARS-CoV-2 show great potential to serve as prophylactic agents K Kangro, M Kurašin, K Gildemann, E Sankovski, E Žusinaite, LS Lello, ... PloS One 17 (6), e0268806, 2022 | 17 | 2022 |
| Human Papillomavirus Type 18 cis-Elements Crucial for Segregation and Latency M Ustav Jr, FR Castaneda, T Reinson, A Männik, M Ustav PloS one 10 (8), e0135770, 2015 | 16 | 2015 |
| Synthetic antibodies neutralize SARS-CoV-2 infection of mammalian cells S Miersch, M Ustav Jr, Z Li, JB Case, S Ganaie, G Matusali, F Colavita, ... BioRxiv, 2020.06. 05.137349, 2020 | 11 | 2020 |
| Nuclear myosin 1 associates with papillomavirus E2 regulatory protein and influences viral replication E Sankovski, A Abroi, M Ustav Jr, M Ustav Virology 514, 142-155, 2018 | 9 | 2018 |
| Broadly neutralizing humanized SARS-CoV-2 antibody binds to a conserved epitope on spike and provides antiviral protection through inhalation-based delivery in non-human primates P Hermet, B Delache, C Herate, E Wolf, G Kivi, E Juronen, K Mumm, ... PLoS Pathogens 19 (8), e1011532, 2023 | 5 | 2023 |
| Molecular Studies of HPV-18 Genome Segregation and Stable Replication M Ustav Jr Dissertationes Technologiae Universitatis Tartuensis, 2016 | 3 | 2016 |
| Method and Kit for Identifying Compounds Capable of Inhibiting Human Papilloma Virus Replication M Ustav, E Ustav, J Geimanen, R Pipits, H Isok-Paas, T Reinson, ... US Patent App. 13/680,618, 2013 | 3 | 2013 |
| Bovine colostrum derived antibodies and uses thereof M Plaas, K Kogermann, E Zusinaite, T Tiirats, B Aasmäe, A Kavak, ... US Patent App. 18/282,143, 2024 | | 2024 |
| Boosted production of antibodies that neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following messenger RNA vaccination-a case study E Ravlo, A Ianevski, E Starheim, W Wang, P Ji, H Lysvand, T Smura, ... International Journal of Infectious Diseases 137, 75-78, 2023 | | 2023 |
| Platform for developing stable mammalian cell lines K Õunap, E Tombak, M Toots, M Jakobson, M Ustav Jr, K Murumets, ... US Patent App. 18/314,979, 2023 | | 2023 |
| Platform for developing stable mammalian cell lines K Õunap, E Tombak, M Toots, M Jakobson, M Ustav Jr, K Murumets, ... US Patent 11,685,936, 2023 | | 2023 |
